Law & policy

Latest content

Brazil’s major patent developments of 2023

Regulation, supreme court decisions and litigation have made for a dynamic year for patents in Latin America’s largest economy

04 January 2024

How the US Supreme Court affected the lives of US IP lawyers in 2023

The Amgen patent enablement ruling was 2023’s crowning gem but the US Supreme Court also issued major trademark decisions and has a host of patent appeals pending

29 December 2023

Isn’t it obvious? Key rulings from the Federal Circuit in 2023

Obviousness decisions trended at the US patent appellate court in the past year and chief IP officers need these practice tips to navigate the changes

28 December 2023

The five stories that made 2023 a transformational year for patents in Europe

The dawn of the unitary patent, Ocado’s ‘robot wars’ triumph, and the Enlarged Board of Appeal’s landmark ‘plausibility’ ruling are among the key developments this year

21 December 2023

Goodbye IAM and thank-you

After 31 years, Joff Wild - our former editor-in-chief - brings down the curtain on his career in IP journalism

21 December 2023

Global first as apex UK court rules AI cannot be a named inventor

But rapid advancements in technology since the government last took the temperature of the market mean questions linger for policymakers

20 December 2023

‘Spreading the gospel’ of holistic IP management

IIPCC president Michael Lin opens up about the Hong Kong-based think tank’s philosophy and says the current worldwide trade secret ecosystem is “chaos”

19 December 2023

Back with a bang: Eastern District of Texas is the most popular patent court

New rules implemented by chief judges in both Western District and Delaware likely turned the tide

18 December 2023

Saturday Opinion: Privacy at stake - the unintended consequences of mandated legal finance disclosure

Chief Judge Colm Connolly spoke at a legal conference about his transparency orders to disclose third-party litigation finance

16 December 2023

Brazil to introduce skinny labels for generic drugs

The decision to allow carve-outs is a blow for patent owners, but is likely to be challenged in the courts

13 December 2023

Unlock unlimited access to all IAM content